Christopher J LaFargue
Overview
Explore the profile of Christopher J LaFargue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
LaFargue C, Amero P, Noh K, Mangala L, Wen Y, Bayraktar E, et al.
Nat Commun
. 2023 Apr;
14(1):2407.
PMID: 37100807
Antiangiogenic treatment targeting the vascular endothelial growth factor (VEGF) pathway is a powerful tool to combat tumor growth and progression; however, drug resistance frequently emerges. We identify CD5L (CD5 antigen-like...
2.
LaFargue C, Handley K, Fleming N, Nick A, Chelariu-Raicu A, Fellman B, et al.
Gynecol Oncol
. 2022 Feb;
165(1):82-89.
PMID: 35216808
Objective: To determine the clinical characteristics of patients who attained pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) and to identify specific predictive or prognostic factors associated with pCR. Methods:...
3.
Ma S, Mangala L, Hu W, Bayaktar E, Yokoi A, Hu W, et al.
Cell Rep
. 2021 Aug;
36(7):109549.
PMID: 34407412
Despite wide use of anti-vascular endothelial growth factor (VEGF) therapy for many solid cancers, most individuals become resistant to this therapy, leading to disease progression. Therefore, new biomarkers and strategies...
4.
Hinchcliff E, Westin S, Dal Molin G, LaFargue C, Coleman R
Int J Gynecol Cancer
. 2019 May;
29(5):956-968.
PMID: 31118216
The use of poly(ADP-ribose) polymerase (PARP) inhibition is transforming care for the treatment of ovarian cancer, with three different PARP inhibitors (PARPi) gaining US Food and Drug Administration approval since...
5.
LaFargue C, Dal Molin G, Sood A, Coleman R
Lancet Oncol
. 2019 Jan;
20(1):e15-e28.
PMID: 30614472
Ovarian cancer remains one of the most challenging malignancies to treat. Targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of the most exciting new treatments...
6.
Dood R, Fleming N, Coleman R, Westin S, Lara O, LaFargue C, et al.
Int J Gynecol Cancer
. 2018 Jul;
28(8):1485-1490.
PMID: 30036226
Objective: Establishing an accurate histologic diagnosis is essential for determining the appropriate course of therapy for ovarian cancer. This study sought to investigate and describe nonovarian cancer pathologies discovered during...
7.
Sawyer B, LaFargue C, Bristow R
Gynecol Oncol
. 2016 Jun;
142(2):378.
PMID: 27264212
Objective: The completeness of primary cytoreductive surgery for Stage IV epithelial ovarian cancer is associated with greater progression free survival and overall survival Winter et al. (2008) [1]. Cytoreduction to...
8.
LaFargue C, Tewari K
Recent Pat Biotechnol
. 2016 Mar;
9(2):86-101.
PMID: 26961668
Ovarian cancer continues to present a significant health challenge with little progress being made over the past two decades in reducing the incidence and mortality. More recently, novel therapeutics have...
9.
10.
Nguyen M, Stevens E, LaFargue C, Karsy M, Pua T, Gorelick C, et al.
JSLS
. 2014 Nov;
18(3).
PMID: 25392626
Background And Objectives: Our aim was to determine whether the use of routine cystoscopy increases lower urinary tract injury detection (bladder and/or ureter) after robotic surgery performed by gynecologic oncologists....